TOP
Nav Bar
  1. General Info
  2. Effects Info
  3. Reference
Drug Interaction Details
01. General Information
Pair Name Sulforaphane, Everolimus
Phytochemical Name Sulforaphane (PubChem CID: 5350 )
Anticancer drug Name Everolimus (PubChem CID: 6442177 )
Structure of
Phytochemical
2D-img
Download
2D MOL 3D MOL
Structure of
Anticancer Drug
2D-img
Download
2D MOL 3D MOL
02. Combinatorial Therapeutic Effect(s)
Synergistic Effect
Hide/Show
Enhancing Drug Efficacy
Hide/Show
Combination Pair ID: 549
Pair Name Sulforaphane, Everolimus
Disease Info [ICD-11: 2C94] Bladder cancer Investigative
Gene Regulation Down-regulation Phosphorylation AKT1 hsa207
Up-regulation Expression AKT1 hsa207
Down-regulation Expression CCNA2 hsa890
Down-regulation Expression CCNB1 hsa891
Up-regulation Phosphorylation CDK1 hsa983
Down-regulation Phosphorylation CDK2 hsa1017
Up-regulation Expression CDKN2D hsa1032
Up-regulation Expression H3C14 hsa126961
Up-regulation Expression HRH4 hsa59340
Down-regulation Expression PSMD9 hsa5715
Down-regulation Phosphorylation RICTOR hsa253260
Up-regulation Phosphorylation RPTOR hsa57521
In Vitro Model RT-112 Bladder carcinoma Homo sapiens (Human) CVCL_1670
UM-UC-3 Bladder carcinoma Homo sapiens (Human) CVCL_1783
TCCSUP Bladder carcinoma Homo sapiens (Human) CVCL_1738
Result The addition of SFN to the long-term everolimus application inhibits resistance development in bladder cancer cells in vitro. Therefore, sulforaphane may hold potential for treating bladder carcinoma in patients with resistance to an mTOR inhibitor.
03. Reference
No. Title Href
1 Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells. Int J Mol Sci. 2020 Jun 4;21(11):4026. doi: 10.3390/ijms21114026. Click
It has been 46307 visits since 2024.08
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang
TOP